<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551328</url>
  </required_header>
  <id_info>
    <org_study_id>452/2014</org_study_id>
    <nct_id>NCT02551328</nct_id>
  </id_info>
  <brief_title>Preconditioning With Sevoflurane and Propofol in Patients Undergoing Minimally Invasive Mitral Valve Surgery</brief_title>
  <acronym>MINI-SEVO</acronym>
  <official_title>A Single-center Observational Study Investigating the Effect of Volatile Conditioning (VC) With Sevoflurane on Myocardial Biomarkers and Platelets Function in Patients Having Minimally Invasive Mitral Valve Surgery (MIMV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Toscana Gabriele Monasterio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Toscana Gabriele Monasterio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to compare markers of cardiac injury (Troponin I), inflammatory
      response and platelets function during minimally invasive mitral valve repair or replacement
      (MIMV) via right mini-thoracotomy in two standard anaesthetic regimes (sevo \propofol)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of this study is to compare markers of cardiac injury (Troponin I), inflammatory
      response and platelets function during minimally invasive mitral valve repair or replacement
      (MIMV) via right mini-thoracotomy in two standard anaesthetic regimes:

        -  Volatile conditioning (sevoflurane) used during induction (preconditioning) and during
           the operation as maintenance (perconditioning) and no propofol.

        -  Propofol induction and maintenance (TIVA) and no volatile anaesthetics.

      Outlet/residual blood samples coming from routine check will be collected at different time
      points.

      Study will be powered on Troponin I (primary statistical outcome). Original secondary outcome
      will be considered: platelets activation, left ventricle function, clinical figures (length
      of stay, inotrops requirements, ventilation times and other relevant).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Injury assessed by changes in Troponin values</measure>
    <time_frame>properatively-6, 12, 24, 48 and 72 hours after the end of ischaemic cardioplegic arrest</time_frame>
    <description>According to the routine post operative blood testing frame-time troponin sample will collected in the preoperative and postoperative period.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Sevofluorane</arm_group_label>
    <description>Patients preconditioned with Sevo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <description>Patients with no preconditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevofluorane</intervention_name>
    <description>Continuous infusion of sevofluorane</description>
    <arm_group_label>Sevofluorane</arm_group_label>
    <other_name>SEVO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Age&gt;=18 Pt undergoing elective (or urgent) first-time minimal invasive mitral valve surgery
        Pt will have to sign informed consent
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥18

          2. Patients undergoing elective (or urgent) first-time minimal invasive mitral valve
             surgery.

        Exclusion Criteria:

          1. Cardiogenic shock or cardiac arrest, emergent CABG

          2. Renal failure (with a GFR &lt; 30 ml/min/1.73m2),

          3. Glibenclamide or nicorandil (as these medications may interfere with VC)

          4. Pregnancy

          5. Known intolerance/allergy to sevoflurane or propofol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Del Sarto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Toscana Gabriele Monasterio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandra Parlanti, Pharmacist</last_name>
    <phone>0039/0585/493675/493565</phone>
    <email>alessandra.parlanti@ftgm.it-parlantialessandra@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale del cuore, Pasquinucci Hospital, Fondazione Monasterio</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Moscarelli, MD</last_name>
      <phone>0044 07587163062</phone>
      <email>m.moscarelli@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dorela Haxhiademi, MD</last_name>
      <email>dorela_h@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>September 15, 2015</last_update_submitted>
  <last_update_submitted_qc>September 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Toscana Gabriele Monasterio</investigator_affiliation>
    <investigator_full_name>MOSCARELLI MARCO</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

